guest ::
| Home > Institute Collections > W500 > Functional binding of PD1 ligands predicts response to anti-PD1 treatment in patients with cancer. |
| Home > Institute Collections > W500 > Functional binding of PD1 ligands predicts response to anti-PD1 treatment in patients with cancer. |
| Journal Article | DKFZ-2025-02470 |
; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
2023
Assoc.
Washington, DC [u.a.]
Abstract: Accurate predictive biomarkers of response to immune checkpoint inhibitors (ICIs) are required for better stratifying patients with cancer to ICI treatments. Here, we present a new concept for a bioassay to predict the response to anti-PD1 therapies, which is based on measuring the binding functionality of PDL1 and PDL2 to their receptor, PD1. In detail, we developed a cell-based reporting system, called the immuno-checkpoint artificial reporter with overexpression of PD1 (IcAR-PD1) and evaluated the functionality of PDL1 and PDL2 binding in tumor cell lines, patient-derived xenografts, and fixed-tissue tumor samples obtained from patients with cancer. In a retrospective clinical study, we found that the functionality of PDL1 and PDL2 predicts response to anti-PD1 and that the functionality of PDL1 binding is a more effective predictor than PDL1 protein expression alone. Our findings suggest that assessing the functionality of ligand binding is superior to staining of protein expression for predicting response to ICIs.
Keyword(s): Humans (MeSH) ; Retrospective Studies (MeSH) ; Ligands (MeSH) ; Neoplasms: drug therapy (MeSH) ; Ligands
; 
; Article Processing Charges ; Clarivate Analytics Master Journal List ; Current Contents - Physical, Chemical and Earth Sciences ; DOAJ Seal ; Ebsco Academic Search ; Essential Science Indicators ; Fees ; IF >= 10 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection ; Zoological Record
|
The record appears in these collections: |
